Immix Biopharma's NXC-201, a BCMA-targeted CAR-T cell therapy, demonstrated a 100% overall response rate in relapsed/refractory AL amyloidosis patients in Phase 1/2a trials.
Nexcella's NXC-201, a BCMA-targeted CAR-T cell therapy, demonstrated a 100% overall response rate in AL amyloidosis patients relapsed or refractory to Darzalex-based regimens.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.